Skip to main content
EuBiologics Co., Ltd. logo

EuBiologics Co., Ltd. — Investor Relations & Filings

Ticker · 206650 ISIN · KR7206650004 KO Manufacturing
Open in API
Filings indexed 425 across all filing types
Latest filing 2020-10-08 Major Shareholding Noti…
Country KR South Korea
Listing KO 206650

About EuBiologics Co., Ltd.

http://eubiologics.com/eng/

EuBiologics Co., Ltd. is a biopharmaceutical company focused on improving global public health through the development and supply of safe and effective vaccines. The company specializes in preventative vaccines against global pandemics and emerging infectious diseases, with a key product being its oral cholera vaccine. In addition to its vaccine pipeline, EuBiologics provides Contract Research and Manufacturing Organization (CRMO) services. These services cover the development and GMP-compliant production of mammalian cell and microbial-derived biopharmaceuticals, including protein-based therapeutics and antibodies. The company is committed to technological innovation and adhering to international standards to address global health challenges.

Recent filings

Filing Released Lang Actions
[기재정정]주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on the Status of Large Shareholdings' (주식등의 대량보유상황보고서) filed with the Financial Supervisory Service (FSS) and Korea Exchange. It details changes in share ownership by a major shareholder (Kim Deok-sang) and special related parties, including acquisition methods, collateral agreements, and funding sources. This type of filing is a standard regulatory disclosure for significant shareholding changes, which falls under the 'Major Shareholding Notification' category.
2020-10-08 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from the Korean Exchange (KRX) system regarding a 'Change in Major Shareholder's Stock Collateral Agreement'. It details the pledging of shares by the major shareholder (Kim Deok-sang) as collateral for loans. This type of disclosure, which involves changes in share ownership status or collateralization by major shareholders, is classified under 'Regulatory Filings' (RNS) as it is a specific corporate disclosure requirement that does not fit into categories like 'Director's Dealing' (which usually refers to personal trades) or 'Share Issue/Capital Change'.
2020-10-07 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a regulatory filing required under the Capital Markets Act in South Korea when an entity's shareholding in a listed company crosses certain thresholds (typically 5%). This document details the changes in share ownership, the purpose of holding (management participation), and specific transaction history. It falls under the category of 'Major Shareholding Notification'.
2020-09-29 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from the Korean Exchange (KRX) system, specifically a 'Correction Report' (정정신고) regarding a 'Stock Collateral Agreement' (주식 담보제공 계약) involving a change in the largest shareholder's holdings. This type of disclosure is a standard regulatory requirement for listed companies to report changes in share pledges or collateralization by major shareholders. Since it does not fit into specific categories like Earnings Release, Annual Report, or M&A, it falls under the 'Regulatory Filings' (RNS) category as the appropriate fallback for miscellaneous corporate regulatory disclosures.
2020-09-28 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from a Korean company (Eubiologics) regarding a 'Correction Report' (정정신고) for a 'Stock Collateral Agreement' (주식 담보제공 계약). This type of filing, which details the pledging of shares by a major shareholder as collateral for loans, falls under the category of capital structure and financing updates. Since it specifically relates to the pledging of shares by a major shareholder, it is classified as a Capital/Financing Update (CAP).
2020-09-08 Korean
신주인수권행사
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing from the Korea Exchange (KRX) system regarding the exercise of stock warrants (신주인수권행사) by Eubiologics. It details the number of shares issued, the exercise price, and the impact on total outstanding shares. This falls under the category of capital changes resulting from the exercise of financial instruments, which is best classified as a Share Issue/Capital Change announcement.
2020-09-07 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.